We developed a panel of highly specific monoclonal antibodies (MAb) to either human or dog collagen Type VI. Various degrees of species aosEreactiviaes were found with ELISA and immunohistology. Because of these differentiating species specifidties, which dowed distiaction between the original donor collagen and newly formed host collagen, the MAb proved to be valuable tools in examination of explanted samples of an ovine composite vascular prosthesis retrieved from a canine model. With an MAb that reacts with dog but not sheep collagen Type VI, newly synthesized pockets of collagen Type VI could readily be detected within the prosthesis as early as 3 months after implantation. These areas were associated with regions of cell infiltration, presumably derived from the host. This association was also apparent in
Introduction
To understand how biomaterials perform in vivo and to assist in the development of biomaterials with enhanced performance, it is necessary to develop critical histological procedures for examining explants retrieved either from animal models or after clinical applications. We have previously discussed the potential for developing monoclonal antibodies (MAb) to connective tissue proteins, particularly collagens, for use in immunohistological examination of biomaterial explants (Werkmeister et al., 1989) . For examining xenografts, these MAb require a high degree of specificity so that they can distinguish among the species of origin as well as the specific types of collagen.
We have previously shown for the fibril-forming interstitial collagens that MAb with the desired degree of specificity can be obtained (Werkmeister and Ramshaw, 1991a,b) . Using these MAb for immunohistological examination of explants of a sheep collagen- the newly formed intimal region of the prosthesis where only host cells were found. Another of the MAb, which was positive against human but not sheep collagen, was also used to demonstrate marked deposition of host collagen Type VI in a retrieved human sample of the prosthesis. In this case the antibody was able to detect collagen on a formalin-fmed tissue, which would broaden the scope of its use in clinical and pathological situations. Use of these novel antibody probes provides a rapid marker for new tissue augmentation of implanted biological devices which would be an indicator of the long-term performance of a prosthesis. (]Histochem Cytochem 41:1701-17W, 1993) based vascular prosthesis (Omniflow Vascular Prosthesis; Bio Nova International, North Melbourne, Australia), we have shown Type V collagen to be a good marker for new tissue development, being associated with the rapid formation of the blood contact surface of the neointima (Werkmeister and Ramshaw, 1991a) . In addition, a panel of different Mab to Type 111 collagen has been used to demonstrate the persistence of the original sheep collagen component of the prosthesis and its augmentation by new host (dog) collagen in samples of prostheses retrieved from dogs after 4 years of implantation as an aortoiliac bypass (Werkmeister et al., 1991) .
These changes in the structure of the vascular implant are important for the long-term durability and performance of the device. For example, maintenance of the original collagen assists in preventing dilatation and aneurysm formation, and augmentation by new tissue also prevents detrimental mechanical changes and leads to better integration with the host, with lower risks of infection.
To develop a device with better performance (e.g., with a diameter suitable for cardiac artery replacement), more rapid shortterm evaluation procedures are needed. In the present study we developed MAb to the non-fibril-forming Type VI collagen. Although the function of Type VI collagen is unknown, it has been suggested to have a broad distribution (Hessle and Engvall, 1984) including a pericellular localization (Mutata et al., 1990; Ayad et al., 1984) , which may indicate areas of new cell migration and collagen synthesis (Murata et al., 1990) . In the present work we developed a range of novel MAb to Type VI collagen for examination of explants of vascular prostheses. The antibodies were able to distinguish between newly formed collagen and the original collagen of the prosthesis. Type VI collagen was readily detected and was associated with cell infiltration of the device.
Materials and Methods
Collagen Samples. Type VI collagen extracts were prepared from dog and sheep skin by the guanidine -action and pepsin solubilization method of Trueb et al. (1987) . except that the final SDS containing step was omitted. Human Type VI collagen was obtained from Hey1 Gmbh (Berlin, Germany). Antibody Preparations. MAb to either human or dog Type VI collagens were prepared using 12-week-old female SJL/J mice. Mice were immunized twice IP with 25 pg human or 200 pg dog Type VI collagen. Three weeks after the second immunization, mice were injected IV with 20 pg human or 100 pg dog Type VI collagen, and after 4 days hybridomas were generated using NS-1 cells as previously described (Werkmeister et al., 1990a) . Antibodies with reactivity against the immunogen were selected by a standard ELISA, using sheep anti-mouse Ig coupled to horseradish peroxidase (Silenus; Melbourne, Australia) as the secondary antibody and 0.5 mg 2.2azino-di-[ 3-ethylbenzthiazoline-sulfonate] ( A m ) (Boehringer; Mannheim, Germany) per ml citrate phosphate buffer containing 0.06% H202 as the substrate (Werkmeister et al., 1990a) . Absorbance values were read at 405 nm with an automatic EAR 400 SF ELISA plate reader (SE Labinstruments; Groedig/Salzburg, Austria). Antibody Characterization. The specificities of the MAb for Type VI collagen were assessed with a panel of other collagen types and connective tissue proteins (Werkmeister et al., 1990a) . Species crossreactivities of the MAb to human, dog, and sheep Type VI collagens were determined by standard ELISA, by immunohistology against skin samples, and by SDS-PAGE (Laemmli, 1970) , using 5% (wlv) running gels and electroblotting onto nitrocellulose; immunostaining was performed as previously described (Ramshaw and Werkmeister, 1988; Towbin et al., 1979) . Antibody subclasses were determined by ELISA with subclass-specific rat anti-mouse MAb and rat anti-mouse Ig coupled to horseradish peroxidase (Pharmingen; San Diego, CA).
Immunohistology. Samples of sheep and bovine skin were obtained from the abattoir, dog skin at autopsy from the Veterinary Research Insti-tute, Parkville, and human skin from The Royal Children's Hospital. Parkville, in compliance with Hospital Ethics Committee protocols. Samples of a sheep collagen-based vascular prosthesis (Omniflow Vascular Prosthesis; Bio Nova International) were kindly provided by the manufacturer after explant from dogs that had received an aortoiliac bypass (Werkmeister et al., 1991) . In addition, a retrieved human explant of Omniflow Vascular Prosthesis was provided by the manufacturer. This formalin-fixed sample had been obtained at autopsy from a patient whose death had been unrelated to prosthesis function. Sections 8 pm thick were cut from frozen tissue samples with a freezing microtome. Tissue sections were examined with the MAb using undiluted culture supernatants by immunofluorescence or by immunoperoxidase as previously described (Werkmeister and Ramshaw, 1991a; Werkmeister et al., 1991) . In control experiments, either the specific MAb was omitted or spent culture supernatant from NS-1 cells or an irrelevant hybridoma line was used. Sections were examined with a Leitz Ortholux I1 microscope, with fluorescence examined with a BioRad (Richmond, CA) Lasersharp MRC-500 confocal imaging system.
Results and Discussion

Characterization of Monoclonal Antibodies
A range of six different MAb were obtained from three fusions, using human or dog collagen Type VI as the immunogen (Table  1) . Reactivity of the MAb for type and species specificity was assessed by ELISA, elecuoblotting, and immunohistology. Compared with previous studies with interstitial collagens in which multiple fusions were often required before a suitable hybridoma was obtained (Werkmeister and Ramshaw, 1991a; Werkmeister et al., 1990a) , Type VI collagen was noticeably more immunogenic, with each fusion producing at least one useful hybridoma cell line. All collagen Type VI preparations, including the commercial source used as immunogens, were highly enriched, although by gel electrophoresis purity was not 100%. Because of the relatively high immunogenicity of collagen Type VI compared with other collagen types found in this study and in others (Linsenmayer et al., 1986; Ayad et al., 1984) , absolute purity of the immunogen was not seen as a major problem. This is consistent with the results of Hessle and Engvall(1984) , who preferentially obtained MAb to type VI collagen when a crude homogenized tissue was used as the immunogen.
By ELISA, the MAb were all highly specific for Type VI collagen (Table 1) and did not show crossreactivity with other collagens, were of human origin and K-elasth was of bovine origin.
Two separate fusions were used for human collagen, as indicated (1) and (2). n.d.. not determined against dog collagen Types I1 and IV, although negative against human collagen Types I1 (0.00) and IV (0.00). Types I, 11,111, IV, and V, or with fibronectin, laminin, or K-elastin. The specificity of each MAb was verified by native and SDS gel electrophoresis and immunoblotting, confirming in all cases that the six MAb shown in Table 1 were all specific against collagen Type VI. The low reactivity sometimes seen against collagen Type V by ELISA was found to be due to these high-affinity antibodies reacting against contaminating Type VI collagen in the preparation. Gel electrophoresis of native collagen Type V and immunoblotting with these MAb showed no reactivity compared with control MAb to collagen Type V (not shown).
The crossreactivities of these MAb were examined by ELISA and by immunohistology. Quantitative data are shown in Table 2 for ELISAs in which antigens from these species were purified. Since all MAb were highly specific against the immunizing collagen Type VI, the degree of species crossreactivity can be easily assessed qualitatively by immunohistology. A range of species specificities was observed ('hble 2). Some MAb were highly specific for the immunogen species, whereas others showed a broader range of crossreactivity. For the MAb raised against human collagen, the observed species specificities suggested that at least three separate epitopes are being recognized.
Previously, for a range of MAb raised against pepsin-soluble fibril-forming collagens Type I, I11 and V (Werkmeister and Ramshaw, 1991a.b; Werkmeister et al.. 1990a) , each MAb was shown to react with conformation-dependent epitopes. In these instances the MAb were unable to detect the separated monomeric a-chains
after SDS-PAGE. In the present study none of the MAb reacted with the heat-denatured monomeric collagen on immunoblotting after SDS-PAGE and Western transfer. Higher molecular weight polymeric bands of Type VI collagen were reactive with the MAb, suggesting that conformation-dependent epitopes are again being recognized.
Tissue Immunohistology
All the MAb were used to examine skin from four species by immunofluorescence (Table 2) . For human, dog, and sheep tissue the data were consistent with the species specificities obtained using ELISA and electroblotting data. In addition, data for specificities against bovine collagen were obtained with immunohistology (Table 2). The staining characteristics of all the MAb were similar and consistent with that reported previously for human skin (Hessle and Engvall, 1984) . The collagen was readily observed throughout the entire dermis ( Figure I) , and no pre-treatment, as is necessary to detect Type V collagen (Werkmeister and Ramshaw, 1991a) , was needed. In all species Type VI collagen was broadly distributed, although no staining of the epidermis or basement membrane was found ( Figure 1A) . Control sections of the same tissue stained with an irrelevant antibody ( Figure ID) or without the primary MAb were always completely negative. In the reticular dermis the staining appeared around larger collagen fiber bundles, which may indicate a close association of collagen Type VI with collagen Type I. The MAb were also reactive by immunogold detection under the electron microscope (not shown). At this level the MAb staining also showed that the collagen Type VI formed a network associated with the interstitial collagen fiber bundles, consistent with previous observations (Keene et al., 1988) . In sheep, there was marked staining around hair follicles (not shown). Although pericellular staining was noted, reactivity of the MAb was not confined to these areas and may simply reflect the accumulation of collagen Type VI in these well-developed tissues.
'
Examination of Biomaterial Explants
The unique species specificities provided by these MAb to Type VI collagen have allowed the host response to a collagen-based vascular prosthesis to be examined. The prosthesis is a sheep collagen-polyester composite, formed when a polyester-covered silicone mandrel is implanted under the cutaneous trunci muscle in sheep for about 12 weeks. After removal from the sheep, the new collagenous tissue was glutaraldehyde-stabilized during the manufacturing process (Perloff et al., 1981) .
After 6 and 12 months of implantation in the dog a small but well-defined neointima is formed (Figure 2A) . We have shown pre- viously that this region, which consists entirely of new host-derived tissue, contains the major fibrillar collagen types (Werkmeister et al., 1989) . More recently, we showed that collagen Type V could be detected very early along the innermost zone of this region and acts as a good marker for new tissue formation in this specialized region close to the blood (Werkmeister and Ramshaw, 1991a) . Unlike the distribution of collagen Type V, Type VI collagen appeared more abundant and uniform throughout the entire thickness of this neointimal region (Figure 2B) . The appearance of this hostderived collagen was intimately associated with marked cell infiltration, presumably fibroblasts migrating from dog advential tissue (Figure 2) . MAb anti-collagen Type VI staining of this neointimal region was specific as judged by comparison with control sections of the same region stained with an irrelevant MAb ( Figure 2C ).
Examination of new collagen augmentation within the main body of the prosthesis, where the original sheep collagen was pres- ent, required the use of an MAb 5C3-ClO1C016, which reacts with dog but not sheep collagen ('lible 2). In addition, because the chemical treatment used during manufacturing leads to strong autofluorescence in the material (Werkmeister et al., 1990b) , a nonfluorescetit detection system, horseradish peroxidase, was used for further immunohistological evaluation (Werkmeister et al.. 1991) . Examination of prosthesis samples that had been in dogs for 3 months showed deposition of new host-derived Type VI collagen infiltrating from around the periphery of the original implant (Figure 3A) . Again, the appearance of collagen Type VI in these areas of tissue augmentation was notably associated with the presence of a considerable number of cells. As a control, the original prosthesis stained with the same MAb appeared less dense, showing no staining, and contained only relatively few cells in this region ( Figure  3B) , indicating that the cells and collagen augmentation observed in the explant ( Figure 3A) were almost entirely due to infiltration from the host.
With either MAb lES-D9/Col6 or 5E4-EblCo16, both of which react with human but not sheep collagen Type VI, similar results were observed for the human sample, which had been explanted after -2.5 years in the subject. Again, Type VI collagen was readily visible in the vessel wall, although in this instance, as with explants from dogs at 6 and 12 months (data not shown), the distribution was more uniform, appearing as a black staining throughout the entire wall of the vessel due to the longer period of implant ( Figure  4A) . Control sections stained with an irrelevant MAb showed the pale gray background of the prosthesis (Figure 4B) . In both sections the original dacron fiber bundles of the prosthesis were visible. Unlike our experience with other MAb to fibrillar collagens, the anti-Type VI MAb were effective on tissue samples that had been fixed in formalin.
Previous studies have suggested that Type VI collagen localizes pericellularly as well as diffusely through the extracellular matrix (Murata et al., 1990; Ayad et al., 1984; Hessle and Engvall, 1984) . Its presence has been thought to indicate cells synthesizing new collagen matrix migrating into the tissue (Murata et al., 1990) . In the present study, detection of this collagen was shown to be a good marker for new tissue associated with rapid cell infiltration of the prosthesis. Furthermore, with the duration of tissue remodeling, Type VI collagen accumulates and appears uniformly distributed throughout the underlying matrix as an indicator of previous cell activity. Although other MAb to chicken and human Type VI collagen have been described (Linsenmayer et al., 1986; Hessle and Engvall, 1984) , the current panel of MAb are unique in their selective and differential reactivity against collagen Type VI from other species. Combined with their ability to react with formalin-fixed tissue, these MAb provide, for the first time, valuable probes to analyze the performance of biological implants from fixed samples retrieved after surgery or autopsy.
